Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Shruti M. Paranjape"'
Autor:
Sarah Jane, Schwarzenberg, Joseph J, Palermo, Wen, Ye, Suiyuan, Huang, John C, Magee, Adina, Alazraki, A Jay, Freeman, Roger, Harned, Boaz, Karmazyn, Wikrom, Karnsakul, Daniel H, Leung, Simon C, Ling, Prakash, Masand, Jean P, Molleston, Karen F, Murray, Oscar M, Navarro, Jennifer L, Nicholas, Randolph K, Otto, Shruti M, Paranjape, Marilyn J, Siegel, Janis, Stoll, Alexander J, Towbin, Michael R, Narkewicz, Estella M, Alonso, Averell H, Sherker
Publikováno v:
Journal of pediatric gastroenterology and nutrition. 75(5)
Cystic fibrosis liver disease (CFLD) begins early in life. Symptoms may be vague, mild, or nonexistent. Progressive liver injury may be associated with decrements in patient health before liver disease is clinically apparent. We examined Health-Relat
Autor:
Marilyn J Siegel, Daniel H. Leung, Jean P Molleston, Wen Ye, Shruti M Paranjape, A Jay Freeman, Joseph J Palermo, Janis Stoll, Prakash Masand, Boaz Karmazyn, Roger Harned, Simon C Ling, Oscar M Navarro, Wikrom Karnsakul, Adina Alazraki, Sarah Jane Schwarzenberg, Alex J Towbin, Estella M Alonso, Jennifer L. Nicholas, Nicole Green, Randolph K Otto, John C Magee, Michael R Narkewicz
Publikováno v:
Journal of Cystic Fibrosis.
Autor:
Beryl J. Rosenstein, Lindsay Jablonski, Peter J. Mogayzel, Carlton K. K. Lee, Shruti M. Paranjape, Alice Pan
Publikováno v:
The Journal of Pediatric Pharmacology and Therapeutics. 25:623-628
OBJECTIVES Clinical practice guidelines for eradication of Pseudomonas aeruginosa (PA) in patients with cystic fibrosis (CF) have been established, but current studies have not assessed how these guidelines translate into clinical practice. This stud
Publikováno v:
F1000Research, Vol 2 (2013)
Background: Host-derived (LL-37) and synthetic (WLBU-2) cationic antimicrobial peptides (CAPs) are known for their membrane-active bactericidal properties. LL-37 is an important mediator for immunomodulation, while the mechanism of action of WLBU-2 r
Externí odkaz:
https://doaj.org/article/33181c6d9f21485ea1fb5e6a4813914d
Publikováno v:
Clinical pediatrics. 59(13)
Autor:
Jean P. Molleston, Shruti M. Paranjape, John C. Magee, Simon C. Ling, Daniel H Leung, Prakash Masand, Karen F. Murray, Averell H. Sherker, Janis Stoll, A. Jay Freeman, Michael R. Narkewicz, Sarah Jane Schwarzenberg, Wikrom Karnsakul, Frank Glen Seidel, Wen Ye, Jennifer L. Nicholas, Marilyn J. Siegel, Estella M. Alonso, Oscar M. Navarro, Roger K. Harned, Boaz Karmazyn, Joseph J. Palermo, Alexander J. Towbin, Adina Alazraki, Randolph K. Otto
Publikováno v:
J Pediatr
To assess if a heterogeneous pattern on research liver ultrasound examination can identify children at risk for advanced cystic fibrosis (CF) liver disease.Planned 4-year interim analysis of a 9-year multicenter, case-controlled cohort study (Prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c64d5e59a50ed243dd17bb8fdc8150
https://europepmc.org/articles/PMC7096278/
https://europepmc.org/articles/PMC7096278/
Publikováno v:
Respiratory Medicine ISBN: 9783030423810
The treatment of cystic fibrosis (CF) pulmonary disease is aimed to optimize pulmonary function and prevent disease progression and other complications through (1) management of chronic infection; (2) clearance of mucous secretions; and (3) reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1753a27059936767d5ad0bae73b4985
https://doi.org/10.1007/978-3-030-42382-7_10
https://doi.org/10.1007/978-3-030-42382-7_10
Autor:
Kerry Vela, Shruti M. Paranjape, Seifu M. Demissie, H. Loosen, Peter J. Mogayzel, Kathryn A. Carson
Publikováno v:
Journal of Acute Care Physical Therapy. 9:136-142
Autor:
H. Loosen, D. Peeler, Peter J. Mogayzel, K. Von Berg, A. Pan, Amanda Leonard, M. Denhard, L. Vanscoy, Shruti M. Paranjape, D. Jordon
Publikováno v:
Journal of Cystic Fibrosis. 20:S39
Autor:
Christian A. Merlo, Jonathan J. Grant, Mark T. Jennings, Noah Lechtzin, Gina Hong, Andrew T. Braun, Rebecca Dezube, Shruti M. Paranjape, Natalie E. West
Publikováno v:
Annals of the American Thoracic Society. 14:1662-1666
In July 2015, the U.S. Food and Drug Administration approved lumacaftor/ivacaftor for use in patients with cystic fibrosis (CF). This drug targets the primary defect in the CFTR protein that is conferred by the F508del CFTR mutation.As there is limit